# Risperidone Augmentation for PTSD

> **NCT00215241** · PHASE2,PHASE3 · COMPLETED · sponsor: **Duke University** · enrollment: 80 (—)

## Conditions studied

- Post-Traumatic Stress Disorder

## Interventions

- **DRUG:** sertraline and risperidone

## Key facts

- **NCT ID:** NCT00215241
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 80 (—)
- **Last updated:** 2014-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00215241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00215241, "Risperidone Augmentation for PTSD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00215241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*